We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Modeling Genetic Circuitry of Cell-To-Cell Communication with Integrated Fluid Circuit Technology

By LabMedica International staff writers
Posted on 26 Aug 2010
Utilizing integrated fluidic circuits (IFCs), researchers have discovered a much larger spectrum of differences between individual cells than has previously been demonstrated. More...
Among these differences are the communication capabilities that emerge from the interactions of genetic circuitry that mediates cell-to-cell communication.

Stanford University (Palo Alto, CA, USA) investigators used Fluidigm Corporation's (South San Francisco, CA, USA) Dynamic Array and Digital Array technology in addition to support instrumentation for its cell culture chip as part of this innovative analysis and modeling on how biologic systems operate at the cellular level.

Stanford University School of Medicine found that, "Cells don't all act in a uniform fashion, as was previously thought. Think of cells as musicians in a jazz band,” said Marcus Covert, Ph.D., assistant professor of bioengineering and senior author of the study, published online in the journal Nature June 27, 2010. Dr. Covert's lab studies complex genetic systems. "One little trumpet starts to play, and the cells go off on their own riffs. One plays off of the other.”

Up to now, most of the scientific data collected on cell signaling has been obtained from populations of cells using bulk assays due to technologic limitations on the ability to examine each individual cell. The new study, using an imaging system developed at Stanford based on microfluidics, revealed that scientists have been misled by the results of the cell-population-based studies, according to the researchers.

"This study represents a triple-play of Fluidigm capabilities. Steve, Markus, and their teams used Fluidigm's Dynamic Arrays and Digital Arrays chips for a large portion of their work and some of our analytical instrumentation in operating the cell culture chip. Their work with cell culture coincides with development work that Fluidigm has underway to develop a Stem Cell Culture Chip for the commercial market under a grant from CIRM [California Institute of Regenerative Medicine],” said Gajus Worthington, president and chief executive officer of Fluidigm.

Fluidigm provides commercially available technology on the market to examine individual cells. This technology enabled these Stanford researchers to look at thousands of individuals cells and conduct a multitude of tests on each cell. Fluidigm researchers said, "Population studies have not revealed the intricate network of information one observes at the single-cell level.

"This really surprised us,” said study coauthor Stephen Quake, Ph.D., a professor of bioengineering at Stanford, and a leader in the field of microfluidics. "It sends us back to the drawing board to figure out what is really going on in cells.”

The study used a combination of Fluidigm 48.48 Dynamic Array IFCs to perform 2,304 quantitative polymerase chain reactions (qPCR) in parallel per chip. The cycle thresholds measured during qPCR reactions were converted into relative expression levels and those expression levels were calibrated for total mRNA molecules per cell using Fluidigm Digital Array IFCs performing digital PCR measurements on a single gene.

"These results highlight the value of high-throughput, quantitative measurements, with single-cell resolution in understanding how biological systems operate. We couldn't agree more,” said Fred Walder, Fluidigm's chief business officer. "The Fluidigm platform is uniquely matched to this emerging and critical biological research reality. As more scientists discover that single-cell understanding is key to life science research, we anticipate dramatically increasing interest and demand for our IFC platform products.”

Fluidigm develops, manufactures, and markets proprietary IFC systems that significantly improve productivity in life science research. Fluidigm IFCs enable the simultaneous performance of thousands of sophisticated biochemical measurements in extremely minute volumes. These "integrated circuits for biology” are made possible by miniaturizing and integrating liquid-handling components on a single microfluidic device.

Related Links:

Stanford University
Fluidigm



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.